Estee Lauder partners with Serpin Pharma to explore Skin Care Longevity Innovations
Global Beauty Conglomerate The Estee Lauder Companies Inc has announced a partnership with biotechnology company Serpin Pharma to developing skin care longevity solutions for its consumers around the world.
Located in Virginia, Serpin Pharma has been researching groundbreaking anti-inflammatory technologies and immune-modulating therapies for over two decades. It has identified Serine Protease Inhibitors (which leverages the body’s innate immune response), that can be applied to address skin irritation, aging, and sensitivity. Estee Lauder aims to explore how their innovative anti-inflammatory research can be translated into cutting-edge skin care solutions.
‘This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery. In partnership with Serpin Pharma, we’re exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide,’ Carl Haney, Executive Vice President, Global Innovation and Research and Development (R&D), The Estee Lauder Companies said in a press release.
‘Serpin Pharma was founded on the principles of biomimicry and how nature solves for signs of trauma and injury, We’re taking a novel approach by tapping into the body’s innate mechanism for resolving inflammation. We are proud to partner with ELC to explore how our powerful biotechnology can be applied to cosmetics and skin care,’ added Cohava Gelber, PhD, MBA, Founder, Executive Chairperson and CEO, Serpin Pharma.
The exclusive partnership will accelerate Estee Lauder’s focus on transformative product innovation and aligns with it’s “Beauty Reimagined” strategy, which focuses on bringing cutting-edge scientific advancements to the beauty industry.
